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Abstract
Background: Resistance to third generation cephalosporins due to acquisition and expression of
extended spectrum β-lactamase (ESBL) enzymes among Gram-negative bacteria is on the increase.
Presence of ESBL producing organisms has been reported to significantly affect the course and
outcome of an infection. Therefore infections due to ESBL isolates continue to pose a challenge to
infection management worldwide. The aim of this study was to determine the existence and to
describe phenotypic and genotypic characteristics of ESBLs in an Intensive Care Unit (ICU) setting
in Tanzania.
Methods: Between October 2002 and April 2003, clinical information and samples were collected
from patients suspected to have nosocomial infections in an Intensive Care Unit of a tertiary
hospital in Tanzania. The isolates were identified, tested for antimicrobial susceptibility and
analysed for presence of ESBL genes.
Results: Thirty-nine Gram-negative bacteria were isolated from clinical samples of 39 patients.
These isolates included 13 Escherichia coli, 12 Enterobacter spp, 5 Pseudomonas spp, 4 Proteus spp, 2
Klebsiella. pneumoniae, 2 Citrobacter freundii and 1 Chryseomonas luteola. Eleven (28.2%) of these
isolates were ESBL producing. The ESBL genes characterised were SHV-12, SHV-28 and CTX-M-
15. The ESBL producing isolates were more resistant to gentamicin and ciprofloxacin than non-
ESBL producing isolates.
Conclusion: This study shows the presence of ESBL genes among Gram-negative bacteria in the
ICU setting in Tanzania. There is a need to institute strict hospital infection control policy and a
regular surveillance of resistance to antimicrobial agents.
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Background
Extended spectrum β-lactamase (ESBL) enzymes have
been reported in a number of species in Gram-negative
bacteria. The ESBL enzymes are usually plasmid mediated
and are capable of hydrolysing and inactivating a wide
variety of β-lactams, including third-generation cepha-
losporins, penicillins and aztreonam, but are susceptible
to β-lactamase inhibitors such as clavulanate, sulbactam
and tazobactam [1,2]. Many ESBL producers also carry
other genes that confer resistance to other antimicrobial
agents such as aminoglycosides and fluoroquinolones
[3,4].
Extensive use of broad spectrum antibiotics, prolonged
hospitalisation, indwelling devices and severe underlying
diseases have been reported as factors that have led to
spread of ESBL and difficulties in managing severe infec-
tions in many parts of the world [5,6].
Treatment of ESBL-producing bacterial infections can
place an added constraint on already overburden health
systems in developing countries. ESBL producing organ-
isms are reported to account for a significant proportion
of intensive care infections [7]. Problems of ESBLs have
led to limited, as well as expensive treatment options, and
have impacted negatively on clinical outcomes [8]. Noso-
comial infections due to ESBL producing organisms have
been known to cause high mortality [9].
Very few studies have reported on the problem of ESBLs in
Africa in general and Tanzania in particular. There have
been reports of CTX -M-12 ESBL in Klebsiella pneumoniae
in Kenya [10], TEM-53, TEM-63, SHV-2, SHV-5, SHV-19,
SHV-20, SHV-21 and SHV-22 in K. pneumoniae in South
Africa [11], CTX-M 15 and SHV-12 in Tanzania [12], SHV-
12 in Salmonella enterica serotype Babelsberg and Entere-
tidis from Mali orphans [13] and TEM-3 in S. typhimurium
in Morocco [14].
The aim of this study was to determine the existence and
to describe phenotypic and genotypic characteristics of
ESBLs in an Intensive Care Unit (ICU) setting in Tanzania.
Methods
Study design
Muhimbili National Hospital is a 1000 bed tertiary health
facility with an eight-bed ICU that caters for surgical, med-
ical and trauma emergencies. During the study period
October 2002 to April 2003, 206 patients were admitted
to the ICU and of these 50 specimens were collected from
patients with suspected nosocomial infections, according
to definitions as described by the Centers for Disease Con-
trol (CDC) [15]. In particular, infections were considered
to be nosocomial if symptoms and signs appeared >48
hours following admission to the ICU.
Bacterial strains and susceptibility testing
Specimen from 50 patients with suspected nosocomial
infections were collected and cultured on blood agar
(Oxoid Ltd, Basingstoke, UK) and MacConkey agar
(Difco/BD Diagnostics Systems, Sparks, MI, USA) except
for urine samples which were plated on Cysteine Lactose
Electrolytes Deficient (CLED) agar. Isolated strains were
stored in tubes containing 1.5 ml Brain Heart Infusion
broth with 10% v/v glycerol at -70°C until the time of
analysis. The isolates were identified using biochemical
tests and confirmed using the API 20E and API 20 NE
identification systems (bioMerieux, Marcy-l'Etoile,
France).
The susceptibility of the Enterobacteriaceae to antimicro-
bial agents was examined by an agar diffusion method
using paper disks (AB Biodisk, Solna, Sweden) containing
the following antibiotic concentration [14]: amoxicillin/
clavulanic acid (20/10 µg), ampicillin (10 µg), ceftriaxone
(30 µg), cefuroxime (30 µg), chloramphenicol (30 µg),
ciprofloxacin (5 µg), doxycycline (30 µg), gentamicin (10
µg) and trimethoprim/sulfamethoxazole (1.25/23.75 µg).
The susceptibility of the non-Enterobacteriaceae was exam-
ined using ceftriaxone, ciprofloxacin, ceftazidime (30 µg),
gentamicin, imipenem (10 µg) and tobramycin (10 µg).
E. coli ATCC 25922 and P. aeruginosa ATCC 27853 were
used as quality control strains.
Testing for presence of ESBL
Gram negative bacteria with reduced susceptibility to
third generation cephalosporins according to the NCCLS
criteria [16], that is, zones of inhibition of = 27 mm for
cefotaxime and = 22 mm for ceftazidime, were tested by
three ESBL Etest strips (AB Biodisk, Solna, Sweden) on
Mueller Hinton agar. Minimum Inhibitory Concentra-
tions of cefotaxime (CT), ceftazidime (TZ) and cefepime
(PM) with and without clavulanic acid were used. The
inoculated plates were incubated for 16–18 hours at
37°C.
ESBL results were read either as MIC values or observation
of 'phantom' zones or deformation of inhibition ellipses.
Reduction of MIC by = 3 two-fold dilutions in the pres-
ence of clavulanic acid was indicative of ESBL production.
Deformation of ellipses or the presence of a 'phantom'
zone was also indicative of ESBL production even if the
MIC ratio is <8 or cannot be read. Isolates were reported
as having ESBL phenotype if one or more of the three
ESBL Etests were positive.
The outcome of the test was indeterminate when MICs
were outside the test range of the test device. Those strains
found to be ESBL producing phenotypically by Etest were
examined for the presence of the TEM, SHV and CTX-M
genes by Polymerase Chain Reaction (PCR).BMC Infectious Diseases 2005, 5:86 http://www.biomedcentral.com/1471-2334/5/86
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Molecular analysis techniques
Isolates with ESBL phenotype were examined for the pres-
ence of blaTEM, blaSHV and blaCTX-M by PCR [17,18]. The
PCR products were purified using QIAquick PCR Purifica-
tion Kits (Qiagen, Hilden, Germany). The templates were
sequenced using the same primers as used in the PCR
amplification. The cycle sequencing parameters were 25
cycles at 96°C for 10 seconds, 58°C for 5 seconds (50°C
for blaCTX-M) and 60°C for 4 minutes. The products were
analysed using an ABI PRISM 3700 DNA sequencer (PE
Biosystems, Warington, UK). Point mutations were
accepted if present in both the forward and reverse
sequences.
Analysis of chromosomal DNA by PFGE
Pulsed-field gel electrophoresis (PFGE) was performed as
described previously by Gautom et al [19]. DNA of all iso-
lates was digested using XbaI (New England BioLabs, Bev-
erly, Mass., USA) at 37°C for 4 hours, according to
supplier's instructions. The slices of the digested DNA
were loaded into the wells of the poured gels. Electro-
phoresis agarose gel (Promega, Madison, USA) with a
concentration of 1% was used for different organisms in
0.5 × Tris-Borate -EDTA buffer using contour -clamped
homogenous electric field apparatus (CHEF-DR III; Bio-
Rad, Richmond, Calif., USA). A 48.5 kb lambda PFG
marker 50 ug/ml (New England BioLabs) was used as a
marker. The conditions for electrophoresis were angle,
120°; gradient, 6 V/cm; temperature, 14°C; pulse times
ranging from 10 to 45 s and running time was 20 hours.
The fragment patterns were interpreted as described by
Tenover et al [20].
Statistical analysis
All statistics were performed by SPSS software 11.5. Con-
tingency table analysis was done by χ2 test or two-tailed
Fisher's exact test for categorical variables. P-value of
<0.05 was considered statistically significant.
Results
Bacteriology and antimicrobial susceptibility pattern
A total of 50 bacteria were isolated from 50 patients sus-
pected of having nosocomial infections. These consisted
of 30 Urinary Tract Infections, 15 wound infections, 3
blood stream infections and 2 cases of pneumonia. Out of
these 50 bacterial isolates, 39 were Gram-negative bacte-
ria, The remaining eleven isolates were S. aureus. These
Gram-negative isolates were identified as Escherichia coli
(N = 13), Enterobacter cloacae (N = 8), Enterobacter aero-
genes (N = 3), Pantoea agglomerans (N = 1), Pseudomonas
aeruginosa (N = 5), Proteus mirabilis (N = 3), Proteus vulgaris
(N = 1), Klebsiella pneumoniae (N = 2), Citrobacter freundii
(N = 2) and Chryseomonas luteola (N = 1).
Among the ESBL producing strains a significant propor-
tion were found to be resistant to antimicrobial agents
including amoxicillin/ clavulanic acid (90.9%), doxycy-
cline (81.5%), gentamicin (72.7%) and trimethoprim/
sulfamethoxazole (90.9%), ceftriaxone (100%) and
cefuroxime (100%). The lowest levels of resistance were
seen for ciprofloxacin and chloramphenicol with 45.5%
each (Table 1). One E. cloacae and one E. coli were resist-
ant to all antimicrobial agents tested. ESBL producing iso-
lates were resistant to more antimicrobial agents than
non-ESBL producing isolates. The highest rates of resist-
ance in ESBL negative isolates were seen against ampicil-
lin (86.4%), doxycycline (77.3%) and trimethoprim/
sulfamethoxazole (63.6%). Pseudomonas spp were fully
susceptible to imipenem, ceftazidime and tobramycin.
The difference in resistance levels between ESBL and non-
ESBL producing isolates for ciprofloxacin (p = 0.017),
ceftriaxone (p = 0.000) and gentamicin (p = 0.003) were
statistically significant (Table 1).
Table 1: Antimicrobial susceptibility pattern of ESBL and non-ESBL producing isolates from the ICU, Dar es Salaam, Tanzania§.
Antimicrobial ESBL (n = 11) Non-ESBL (n = 22) p-value
% resistant % resistant
Amoxicillin/Clavulanic 90.9 72.8 0.451
Ampicillin 100 86.4 0.521
Ceftriaxone 100 13.6 0.000
Cefuroxime 100 72.7 0.151
Chloramphenicol 45.5 27.3 0.514
Ciprofloxacin 45.5 4.5 0.017
Doxycycline 81.8 77.3 0.880
Gentamicin 72.7 13.6 0.003
Trimethoprim/Sulfa. 90.9 63.6 0.214
Pseudomonas spp and C. luteola were excluded in this analysis§.BMC Infectious Diseases 2005, 5:86 http://www.biomedcentral.com/1471-2334/5/86
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PCR and sequencing of ESBL genes
All Gram-negative isolates except for Pseudomonas spp were
screened for ESBL. The eleven isolates that were phenotyp-
ically positive for ESBL were tested by PCR. Six, seven and
five isolates were positive for blaTEM, blaSHV and blaCTX-Mre-
spectively (Table 2). One isolate each of E. coli, K. pneumo-
niae and E. cloacae had both blaTEM and blaSHV>. One K.
pneumoniae isolate had only blaSHV, three isolates of E. coli
had both blaTEM and blaCTX-M and two isolates of E. cloacae
had both blaSHV and blaCTX-M. One E. cloacae isolate was
phenotypically ESBL positive on Etest but was negative for
blaTEM, blaSHV and blaCTX-M on PCR.
Nucleotide sequence analysis of the isolates carrying
blaCTX-M revealed that all isolates carried the CTX-M-15
gene. Of the seven isolates that had bla SHV, six had SHV-
12 and one had SHV-28 (Table 2). TEM-1 was identified
in TEM producing isolates.
Genotypic relationship of the ESBL isolates
Two of the 13 E. coli isolated had indistinguishable restric-
tion patterns on PFGE. These were isolates from two dif-
ferent patients and from different specimen (urine and
pus). The two patients had at one time been together in
the ICU. Other isolates tested were unrelated.
Discussion
This study demonstrates the presence of ESBL-mediated
resistance in bacteria causing infections in the ICU of a ter-
tiary hospital in Tanzania. Despite the rise in the preva-
lence of ESBL in some countries, there are very few reports
from Africa [10-12,14]. ESBL detection is not commonly
carried out in many microbiology units in developing
countries, Tanzania included. This could be attributed to
lack of awareness and lack of resources and facilities to
conduct ESBL identification. The high rate of resistance
noted among the isolates in the present study, although
few in numbers, is of serious concern. Eleven of the 39
(28.2%) of the Enterobacteriaceae were ESBL producing.
In this study, ESBL producing isolates were significantly
more resistant to ciprofloxacin (p = 0.017), ceftriaxone (p
= 0.000) and gentamicin (p = 0.003) as compared to non-
ESBL producing Gram-negative isolates. Other studies
have reported on cross-resistance to aminoglycosides,
fluoroquinolones and trimethoprim/sulfamethoxazole in
ESBL producing organisms [21,22]. Mechanisms of co-
resistance are not clear, but one possible mechanism is the
co-transmission of ESBL and resistance to other antimi-
crobials within the same conjugative plasmids [23].
This study reports on the presence of CTX-M-15 produc-
ing isolates in the ICU setting in Tanzania. CTX-M-15 gene
was also found among bloodstream infection isolates
from children within the same hospital [12]. This gene is
widespread in European and Asian countries including
Northern Italy [18], United Kingdom [24] and India [25].
The other reported gene is CTX-M-12 that was identified
amongst K. pneumoniae isolates from cerebrospinal fluid
and blood in Kenya [10]. In the present study, the CTX-M-
15 gene was found in two different genera of the bacterial
isolates in the ICU (E. coli and E. cloacae). Two of the CTX-
M-15 producing isolates were also found to possess the
SHV-12 gene. The two E. coli with indistinguishable PGFE
restriction patterns were found to be resistant to all anti-
microbials tested except for chloramphenicol.
SHV-12 was found in the two strains of E. coli with indis-
tinguishable PFGE restriction patterns. SHV-12 was also
found among bloodstream infection isolates from chil-
Table 2: Characteristics of ESBL producing isolates from ICU, Dar es Salaam, Tanzania.
Organism ESBL enzyme Date of Isolation Specimen
E. cloacae SHV-12, CTX-M-15 13 December 2002 pus
" SHV-12, CTX-M-15 27 October 2002 urine
" SHV-12 30 December 2002 urine
" -* 16 February 2002 urine
E. aerogenes SHV-12 18 October 2002 urine
E. coli SHV 12 22 October 2002 urine
" CTX-M-15 28 November 2002 urine
" CTX-M-15 05 December 2002 urine
" CTX-M-15 30 November 2002 pus
K. pneumoniae SHV-12 30 December 2002 pus
" SHV-28 20 February 2003 urine
*Isolate no.5 (E. cloacae) was phenotypically positive on E-test but negative on PCR.BMC Infectious Diseases 2005, 5:86 http://www.biomedcentral.com/1471-2334/5/86
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dren within the same hospital [12]. This gene has also
been reported in several European and Asian countries
including Switzerland [26] and Thailand [27].
In the present study, this gene was found across different
genera of bacterial isolates. The other SHV related genes
that have been reported in Africa include SHV-2, SHV-5,
SHV-19, SHV-20, SHV-21 and SHV-22 that were reported
in South Africa [11].
In this study, one K. pneumoniae isolate was found to pos-
sess SHV-28. Initial reports of this gene came from China
(GenBank accession no. AF299299). To the best of our
knowledge, there are no other reports of this gene in the
literature. This isolate was obtained from a urine speci-
men from a patient with urinary tract infection. This iso-
late was resistant to amoxicillin/clavulanic acid,
doxycycline and trimethoprim/sulfamethoxazole and
cephalosporins but sensitive to chloramphenicol, cipro-
floxacin and gentamicin.
Presence of similar SHV, TEM and CTX-M genes in various
non-genetically related strains suggests a possibility of
horizontal transfer of these genes in the ICU. On the other
hand, the two E. coli that produced indistinguishable
restriction patterns on PFGE suggests that clonal spread of
the resistant bacteria is also a potential factor in the spread
of resistance in the ICU. These finding of similar ESBL
genes in the ICU and in paediatric wards [12] within the
same hospital could mean the ESBL genes are widespread
in this hospital.
Conclusion
This study shows that there is a presence of ESBL produc-
ing isolates in the ICU of a major hospital in Tanzania.
This is also the first report of presence of SHV-28 in Africa.
This study also shows that the ESBL phenotype spread in
this hospital is due to multiple enzymes found in different
genera of bacteria. There is a need to institute a strict hos-
pital infection control policy and a regular surveillance of
resistance to antimicrobial agents.
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